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Abstract
Background: The current paper introduces the actual International College of Neuro-Psychopharmacology clinical guidelines 
for the treatment of bipolar disorder.
Concept and structure of the guidelines: The current clinical guidelines are based on evidence-based data, but they also 
intend to be clinically useful, while a rigid algorithm was developed on the basis of firm evidence alone. Monotherapy was 
prioritized over combination therapy. There are separate recommendations for each of the major phases of bipolar disorder 
expressed as a 5-step algorithm.
Discussion: The current International College of Neuro-Psychopharmacology clinical guidelines for the treatment of bipolar 
disorder are the most up-to-date guidance and are as evidence based as possible. They also include recommendations 
concerning the use of psychotherapeutic interventions, again on the basis of available evidence. This adherence of the 
workgroup to the evidence in a clinically oriented way helped to clarify the role of specific antidepressants and traditional 
agents like lithium, valproate, or carbamazepine. The additional focus on specific clinical characteristics, including 
predominant polarity, mixed features, and rapid cycling, is also a novel approach.Many issues need further studies, data are 
sparse and insufficient, and many questions remain unanswered. The most important and still unmet need is to merge all 
the guidelines that concern different phases of the illness into a single one and in this way consider BD as a single unified 
disorder, which is the real world fact. However, to date the research data do not permit such a unified approach.
Keywords: bipolar disorder, anticonvulsants, antidepressants, antipsychotics, evidence-based guidelines, lithium, mania, 
bipolar depression, mood stabilizers, treatment, clinical trials
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Introduction
The current paper is the third in the series of The International 
College of Neuro-Psychopharmacology (CINP) papers concerning 
the development of clinical guidelines for the treatment of bipo-
lar disorder (BD) in adults in primary and secondary care. This 
guideline is the first on the treatment of BD that is developed 
by the CINP and concerns the treatment of adult patients with 
BDr-I or II, with mixed features, rapid cycling, and psychotic fea-
tures but not children, adolescents, or the elderly. It is designed 
for use mainly by psychiatrists in secondary care, but it might be 
also useful in primary care settings. The current guidelines were 
developed by a group of experts in the field after a systematic 
and comprehensive review of the literature and thus they are as 
evidence based as possible but also suitable for use in everyday 
clinical practice of busy clinicians. No analysis of cost or other 
issues other than efficacy and safety/tolerability were taken into 
consideration when developing these guidelines.
During the last few decades there were important develop-
ments both in our understanding of BD but also in its treatment 
(Fountoulakis, 2015a, 2015b, 2015c, 2015d, 2015e, 2015f). In many 
instances the accumulation of new knowledge challenged old 
beliefs that dominated the psychiatric academic thinking and 
practice for decades. It is hoped that these guidelines will assist 
clinicians, patients and their families, and society in general to 
benefit from the advances in research and translate them into 
everyday clinical practice. It should be made clear, however, that 
guidelines are not a substitute for professional knowledge and 
clinical judgement, and therefore their use is at the discretion of 
the clinical psychiatrist after taking into consideration the unique 
characteristics and needs of the specific patient. It is important to 
have in mind that this guideline does not override the responsi-
bility of the therapist to arrive at the appropriate decisions, espe-
cially since the final choice of treatment will demand the consent 
and acceptance of the patient and his caretakers and family.
When considering the recommendations of these clinical 
guidelines, it is important to remember that treatment and care 
of psychiatric patients is best done within a multidisciplinary 
setting that engages both the patient and his or her family in 
the treatment plan. Such setting should also provide advice 
concerning any direct or indirect effects the disorder has on the 
lives of the patient and his or her family members.
All members of the workgroup made formal declarations of 
interest that are included at the end of all the published papers 
of this series. Eleven members oversaw the analysis and syn-
thesis of research data and the development of the guideline, 
and all statements and recommendations in this guideline have 
been agreed upon by the whole workgroup.
The clinical guidelines that are included in the current paper 
are as much evidence based as possible and by this, they put an 
ever stronger emphasis on evidence than other expert consen-
sus guidelines. However, clinical wisdom and practical issues 
helped to shape the guidelines in a user-friendly way.
The CINP workgroup developed a precise algorithm and a detailed 
guideline that are both included in the 2nd paper of this series, while 
the current paper includes the simpler clinical guideline.
Details on efficacy and recommendation levels for each 
treatment modality are included in the 2nd paper of this series, 
which is also included in the current issue of the journal.
Existing Evidence for the Treatment of BD
As shown and discussed in detail in the previous manuscripts of 
the CINP BD guidelines, there are a significant number of studies 
that have reported original data or results of posthoc analyses 
and meta-analyses for the treatment of acute mania, and these 
studies/analyses have addressed monotherapy, combination or 
add-on treatments as well as the comparison of some of these 
treatment options. Unfortunately, the literature is rather lim-
ited for acute bipolar depression and the maintenance phase 
in terms of monotherapy, combination treatment, and compari-
son of agents as well as posthoc and meta-analyses. There is 
also limited literature on the treatment of mixed episodes, rapid 
cycling patients, comorbid conditions, and special issues. In 
addition to the data from the clinical trials, the workgroup took 
into consideration recommendations from the already existing 
guidelines, with specific emphasis on those developed during 
the last 10 years.
Concept and Structure of the Clinical 
Guidelines
As mentioned before, the current guidelines are based on hard 
data and were intended to be as evidence based as possible 
while recognizing that there is not enough evidence available 
for all phases and facets of BD and that guidelines should be 
user friendly to be used widely in everyday clinical practice. 
When developing the guidelines, monotherapy was given prior-
ity over combination therapy when data were sufficient to do so. 
The guidelines give separate recommendations for each of the 
major phases of BD, that is, acute mania, acute bipolar depres-
sion, and the maintenance phase. It is strongly recommended 
that the clinician when applying the recommendations for the 
acute phase keeps the long-term treatment needs in mind.
One of the major challenges was the issue of mixed epi-
sodes vs mixed features, as DSM-IV-TR and DSM-5 have a dif-
ferent approach (Vieta and Valenti, 2013). Controlled studies use 
DSM-IV-TR definitions, while at the same time most countries 
have the obligation to use ICD-10 for clinical purposes. To make 
things even more complex, the data suggest that mixed features 
respond to treatment in a different way than mixed episodes do 
(according to DSM-IV-TR definition).
Another challenge was the use of the term “mood stabilizer.” 
Although there is controversy on the true meaning of the term 
given the findings from recent randomized controlled trials, 
the term is retained in the phrasing of the guidelines when it is 
impossible to avoid it, since a number of studies utilize it and do 
not differentiate between the agents that had been used. When 
used in the guidelines, the term usually refers to lithium, val-
proate, and in some instances to carbamazepine and lamotrigine.
Clinical Guidelines to Treat Bipolar Disorder
General Guidelines
The first priority when dealing with a BD patient is the assess-
ment of risks to the patient or others, and whether there is a 
need for immediate hospitalization, even involuntary. It is 
important to provide a tranquil environment with reduced stim-
uli for patients in an acute manic or hypomanic episode. Both 
the patient and the family should be advised that all important 
decisions including family matters, professional issues, and 
finances should be postponed until the resolution of the acute 
symptomatology. On the other hand, during an acute depres-
sive or mixed episode, the patients are at a higher risk to com-
mit suicide, and every measure to protect the life of the patient 
should be taken.
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Establishing a therapeutic alliance with the patient and his/
her family and caregivers is of utmost importance, although it 
could be difficult especially during periods of acute mania and 
in the presence of psychotic features. Involuntary admission 
might be unavoidable when the health and the life of the patient 
or others might be at risk; however, the dignity, human rights, 
and personal space of the patient should be respected, as law 
dictates.
As soon as this is feasible, a full physical examination of 
the patient should be conducted, including laboratory testing. 
Women should also be assessed for polycystic ovary syndrome 
(PCOS). The physical examination and laboratory testing should 
be repeated according to local guidance and the clinical judge-
ment of the therapist especially in response to changes in the 
clinical picture. It is advisable to repeat laboratory testing after 
1 month and every 3 to 6 months thereafter, also depending on 
the medications prescribed.
Similar to epilepsy, there is an association between PCOS 
and major psychiatric disorders, including BD. An increased 
risk can also be demonstrated in their siblings suggestive of 
shared familial factors between PCOS and psychiatric disorders. 
Obesity as well as the use of valproate could be another risk fac-
tor connecting mental disorders with PCOS (Cesta et al., 2016).
Whenever possible patients should participate in decision 
making concerning the treatment plan. Psychoeducational 
interventions will be beneficial for such involvement. Such par-
ticipation in decision making usually improves adherence and 
collaboration with the therapist, thus leading to a better out-
come. Close collaboration between the patient, his/her family, 
and the therapist may improve identification of periods with 
a high risk of relapse and timely adjustments of treatment to 
reduce the intensity and duration of an emerging acute episode.
The acute treatment should be tailored to the individual 
patient needs and specific clinical characteristics in terms of 
medication choice and dosage according to the recommenda-
tions made by the guidelines. The dosage should be titrated 
according to clinical judgement and eventually be raised to 
the highest recommended and tolerated dose to maximize the 
chances for treatment response. Therapeutic drug monitoring 
may be a helpful tool in selected, nonresponsive patients.
Decreased need for sleep is a common symptom of mania 
and difficulty to fall asleep is a frequent symptom of depres-
sion. Further, sleep disturbance can destabilize the course of BD 
and can also be an early warning sign of impending relapse of 
mood episodes. Therefore, clinicians need to be particularly vigi-
lant to addressing sleep disturbance in order to aid recovery in 
those with acute mood episodes and prevent relapse of mood 
episodes in BD patients during maintenance treatment.
Most clinicians tend to use antipsychotics in manic patients 
with psychosis, and there is evidence that antipsychotics are 
equally effective in those with and without psychotic mania. 
However, the studies have not systematically assessed the effi-
cacy of lithium or other mood stabilizers with regard to whether 
they work equally well in both populations. Therefore, we rec-
ommend using antipsychotics in psychotic manic patients and 
adding them to those on mood stabilizers that are unresponsive.
The latency until response varies, although in acute mania 
an observable improvement of symptoms may occur within 
the first few days, especially with the use of antipsychotics. 
Response to lithium might take at least a week, while with 
valproate or carbamazepine it might take longer, but response 
should be observable within the first 2 weeks. Beyond this manic 
patients should be considered as nonresponders to the specific 
agent(s) at the specific dosage(s). For acute bipolar depression 
and mixed patients response to treatment could take longer and 
improvement may be more subtle.
The successful treatment of the acute episode should be 
continued during the adjacent phase, which is called continua-
tion, and may differ from the maintenance phase, although the 
terms are often interchangeably used.
The position of the CINP guidelines is that the acute phase 
treatment should be continued with the same medication and at 
the same dosage for a minimum of 2 months after the achieve-
ment of full resolution of manic symptoms (and thus the patient 
has entered remission) and for at least 6 months if the index epi-
sode was bipolar depression. After this period treatment should 
either be continued or gradually switched to the recommended 
maintenance treatment. This recommendation was reached 
through expert consensus on the basis of clinical wisdom, since 
there are no hard data to rely on. In most patients, maintenance 
treatment should be kept indefinitely (lifelong) after the diagno-
sis of BD has been confirmed. Exceptions may be patients after a 
first and single manic or mixed episode, and those with a history 
of a very low relapse rate where physical health risks of medi-
cation may outweigh benefits. This should be a special issue to 
deal with during psychoeducational interventions.
As discussed in detail in the specific papers, BD is associ-
ated with an increased comorbidity that includes alcohol and 
substance abuse, anxiety disorders, personality disorders, and 
higher rates of general medical conditions. The management of 
these comorbid conditions and especially of those medical con-
ditions that are associated with reduced life expectancy should 
be considered as high priority.
In essence, BD is a chronic disease with a complex clini-
cal picture, in need of complex and expensive treatments, 
and associated with high psychiatric and medical comorbidity 
(Grande et al., 2016). High-quality, intensive care is needed, ide-
ally in the frame of a multidisciplinary team and with step-wise 
interventions and activities that also extend in the community 
(Wagner, 1998).
The levels of recommendation concerning monotherapy and 
combination treatment in acute mania and mixed episodes as 
well as the recommended dosages of medication are depicted in 
Table 1. Effects on the manic and the depressive components of 
mixed episodes are shown separately.
Clinical Guidelines for the Treatment of Acute 
Mania/Hypomania
Patients with acute mania/hypomania should be evaluated 
immediately upon presentation concerning the risk of violent 
and dangerous behaviors. Impulsiveness should also be evalu-
ated, since its combination with grandiose thinking might pose 
the patient at a high risk to hurt herself or himself or others. 
In potentially or acutely agitated patients, it is important to 
provide a calming environment with reduced stimuli (Garriga 
et al., 2016).
Next, rapport with the patient should be established, if pos-
sible, to assess the degree of insight and ability to collaborate to 
receive treatment as well as the need for hospitalization. This 
should be followed by a thorough physical examination includ-
ing laboratory testing; however, in many cases it is inevitable to 
postpone it until the patient is more cooperative.
In the absence of reliable data, hypomania should be treated 
similarly to full mania, although higher doses may be required 
for the latter. Besides the specific medication recommendations 
as depicted in Table  1, there are some general principles that 
should be obeyed:
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First step:
• Discontinue treatment with antidepressants
• Take into consideration any previous history of psychotic 
features
• Start with aripiprazole, asenapine, cariprazine, paliperidone, 
quetiapine, risperidone, or valproate monotherapy
• If the patient is already under one of the above first-step mono-
therapy or under combination therapy of any kind and response 
is unsatisfactory, switch to another first-step monotherapy
• If the personal history of the patient suggests that this is not 
an option, proceed to the next step and switch to the most 
suitable second-step treatment option based on treatment 
response and tolerability issues during previous episodes.
Second step:
If the interventions recommended during the first step fail or 
the response is unsatisfactory, then apply:
• Olanzapine, lithium, carbamazepine, haloperidol, or ziprasi-
done monotherapy
• Combinations of lithium or valproate plus asenapine, ari-
piprazole, haloperidol, olanzapine
• Lithium plus allopurinol*
• Valproate plus a first-generation antipsychotic (FGA)
• Valproate plus celecoxib*
Third step:
• Combination treatment of lithium or valproate with quetia-
pine or risperidone
Fourth step:
• Apply ECT on top of pharmacological treatment or switch to 
oxcarbazepine monotherapy
• The fourth step includes monotherapy with chlorpromazine, 
pimozide, tamoxifen options are also combination treat-
Table 1. Level of Recommendation Concerning Monotherapy in Acute Mania/Mixed and Recommended Dosages for Medication Options
Acute Mania Mixed Episode
Mono
therapy Combination Monotherapy Combination with MS
Agent/modality MS Li Val Cbz FGAs Manic 
component
Depressive 
component
Manic 
component
Depressive 
component
Recommended 
dosage (mg/d)
Aripiprazole 1 2 - - - - 3 3 - - 15-30 
Asenapine 1 2 - - - - 3 3 - - 10-20 
Cariprazine 1 - - - - - - - - -  3-12
Paliperidone 1 5 - - - - 3 5 - -  3-12
Quetiapine 1 2 2 - - - 5 - - - 400-800 
Risperidone 1 2 - 5 - - 3 - 5 5 2-6 
Valproate 1 - - - - 2 3 4 - - 1200-3000 (loading 
dose 20-30 mg/
kg body weight; 
serum level  
75-150 mg) 
Carbamazepine 2 - - - - - 3 3 - - 600-1200 (serum 
level 4-15 mg/l)
Haloperidol 2 2 2 2 2 - - - 5 5 5-20 
Lithium 2 - - - 2 - 5 - - - 600-1200  
(serum level 
0.8-1.3 mmol)
Olanzapine 2 2 - 2 5 - 3 3 2 2 10-20 
ECT 3 - - - - - - - - -  
Oxcarbazepine 3 - 2 - - - - - - -  900-1800
Chlorpromazine 4 - - - - - - - - -  300-1000
Pimozide 4 - - - - - - - - -  2-16
Tamoxifen 4 4 4 - - - - - - -  40-80
Ziprasidone 4 5 - - - - 4 4 - - 80-160 
OFC - - - - - - 4 4 - - 6 and 25, 6 and 50, 
12 and 50 
Medroxyprogesterone - 2 - - - - - - - - 20 
Allopurinol - 5 2 - - 5 - - - - 300-600 
Celecoxib - - - - - - - - 5 5
Eslicarbazepine 5 - - - - - - - - -
Gabapentin 5 5 - - - - - - - -
Lamotrigine 5 - - - - - - - - -
Licarbazepine 5 - - - - - - - - -
rTMS 5 - - - - - - - - -
Topiramate 5 5 - - - - - - - -
Verapamil 5 - - - - - - - - -  
FEWP - - - - 5 - - - - -
Abbreviations: -, no data; Cbz, carbamazepine; ECT, Electroconvulsive therapy; FEWP, Free and Easy Wanderer Plus; FGA, first-generation antipsychotic; MS, mood 
stabilizer; NR, not recommended; OFC, olanzapine-fluoxetine combination; rTMS, repetitive Transcranial Magnetic Stimulation; Val, valproate.
The grading method including the levels of recommendation are described in detail in the 1st and 2nd papers on CINP treatment guidelines, which are included in 
the current supplement.
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ments of lithium or valproate plus tamoxifen, or the combi-
nation of risperidone plus lithium. In patients with residual 
manic/hypomanic symptoms, oxcarbazepine addition to 
lithium may be helpful.
• If a full mixed episode according to DSM-IV criteria is pre-
sent, then the choice should be olanzapine-fluoxetine com-
bination (OFC) or ziprasidone monotherapy
Fifth step:
• Various combinations of medication according to anecdotal 
knowledge or the personal experience of the therapist; ECT 
if not applied earlier
Not recommended:
• Monotherapy with eslicarbazepine, gabapentin, lamotrigine, 
licarbazepine, rTMS, topiramate, verapamil
• Combination therapy of lithium or valproate plus paliperi-
done, ziprasidone, gabapentin, topiramate or Free and Easy 
Wanderer Plus (FEWP) and the combination of allopurinol 
plus a mood stabilizer (other than lithium) or an FGA (other 
than chlorpromazine or haloperidol)
• Medroxyprogesterone plus a mood stabilizer
• Valproate is not suitable for women of child bearing age
Note:
* no wide clinical experience
Recommendation of dismissing a treatment option is 
based on the efficacy and safety of this specific treatment 
option in acute mania. However, an agent or treatment 
modality that is otherwise not recommended during the 
acute phase could be added for specific reasons (e.g., start-
ing with lamotrigine early during mania to prevent future 
depressive episodes in patients with depressive predomi-
nant polarity or topiramate for weight reduction.)
The step-wise algorithm for acute mania/hypomania is shown 
in Table 2. Comparison of the CINP guidelines to various other 
previously developed guidelines for acute mania is shown in 
Table 3.
Clinical Guidelines for the Treatment of Acute 
Bipolar Depression
The assessment of suicidal and self-harm risk has priority in 
BD patients with an acute depressive episode. Next, insight 
and willingness to adhere to the treatment plan as well as 
the social support network should be evaluated. Based on 
this information, a decision whether hospitalization (even 
involuntary) is mandatory should be made. An overview of 
the study data this clinical guideline is based on is shown in 
Table 4.
The following stepwise treatment algorithm has been put 
forward by the task force:
First step:
• Start with quetiapine or lurasidone
• Consider CBT as add-on to medication according to the 
patient preference and to availability. Never consider CBT as 
monotherapy
Second step:
• Monotherapy with olanzapine or OFC
• Combination of a mood stabilizer with lurasidone, modafinil, 
or pramipexole
• Lithium plus lamotrigine or pioglitazone*
• Add escitalopram or fluoxetine to ongoing therapy
• For the treatment of comorbid anxiety add paroxetine, que-
tiapine, valproate, or lurasidone, and consider mindfulness-
based interventions as add-on to ongoing therapy
Table 2. Clinical Guideline to Treat Acute Manic and Mixed Episodes
1st step • Discontinue treatment with antidepressants
• Take into consideration the previous history of psychotic features
• Start with aripiprazole, quetiapine, cariprazine, paliperidone, quetiapine, risperidone, valproate, or asenapine 
monotherapy
• Consider IPSRT as add-on to medication according to clinical judgement, patient preferences and availability. Never 
utilize IPSRT as monotherapy
2nd step Apply
• Olanzapine, lithium, carbamazepine, or haloperidol monotherapy
• Combinations of lithium or valproate plus aripiprazole, haloperidol, olanzapine, quetiapine, or risperidone
• Lithium plus allopurinol or oxcarbazepine
• Valproate plus a FGA
• A mood stabilizer plus medroxyprogesterone
• Valproate plus celecoxib
3rd step • ECT on top of pharmacological treatment
• Oxcarbazepine monotherapy.
4th step • Monotherapy with chlorpromazine, pimozide, tamoxifen, or ziprasidone.
• Combination of lithium or valproate plus tamoxifen
• Combination of risperidone plus lithium
• OFC or ziprasidone monotherapy in mixed episodes
5th step • Various combinations of medication according to anecdotal knowledge or the personal experience of the therapist
• ECT if not applied earlier
Not recommended Monotherapy with eslicarbazepine, gabapentin, lamotrigine, licarbazepine, rTMS, topiramate, verapamil, and 
combination therapy of lithium or valproate plus paliperidone, ziprasidone, gabapentin, topiramate or FEWP and the 
combination of allopurinol plus a mood stabilizer (other than lithium) or an FGA
Abbreviations: ECT, electroconvulsive therapy; FEWP, Free and Easy Wanderer Plus; FGA, first-generation antipsychotic; IPSRT, interpersonal and social rhythms 
therapy; OFC, olanzapine fluoxetine combination;rTMS, repetitive Transcranial Magnetic Stimulation.
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Third step:
• Valproate, aripiprazole, imipramine, phenelzine, or lamotrig-
ine monotherapy
• Lithium plus L-sulpiride
Fourth step:
• Start with tranylcypromine or lithium monotherapy
• Venlafaxine in combination with an antimanic agent
• Armodafinil or intravenous ketamine in combination with a 
mood stabilizer
• Lithium plus fluoxetine or lamotrigine
• Carbamazepine plus FEWP
• Levothyroxine (L-T4) plus a mood stabilizer
• Lithium plus oxcarbazepine
Fifth step:
• ECT
• Various combinations of medication according to anecdotal 
knowledge or the personal experience of the therapist
Not recommended:
• Monotherapy with donepezil, paroxetine (except for comor-
bid anxiety), ziprasidone, gabapentin, and TMS
• Combination of any mood stabilizer with agomelatine, 
paroxetine, ziprasidone, bupropion, celecoxib, levetiracetam, 
lisdexamfetamine, risperidone, or pregnenolone
• Memantine plus lamotrigine
• Lithium plus aripiprazole, donepezil, or imipramine
• Risperidone or ziprasidone for concomitant anxiety
Note:
* no wide clinical experience
Some agents may put the patient at a higher risk to switch 
(e.g., antidepressants or stimulants) (Pacchiarotti et al., 2013). 
In spite of the monotherapy recommendation, it is at the ther-
apist’s discretion to add an antimanic agent as a prophylactic 
measure, since, for most of these agents and contrary to com-
mon believes, the data are negative or equivocal for switching.
The stepwise algorithm for acute bipolar depression is 
shown in Table  5. The comparison of the CINP guidelines to 
other previously developed guidelines for acute bipolar depres-
sion is shown in Table 6.
Clinical Guidelines for the Treatment during the 
Maintenance Phase
It is expected that during the maintenance period, most patients 
should have full capacity to participate in decisions concerning 
her/his treatment plan, especially if they have had psychoedu-
cational interventions. Such participation in decision making 
not only is in accord with social and political ethics, human 
Table 3. Comparison of CINP Clinical Guidelines to Other Previously Developed Guidelines for Acute Mania
CINP 2017 WFSBP 2013a CANMAT and ISBD 2013 NICE 2014b BAP 2016b
Aripiprazole 1 1 1 - 3
Asenapine 1 2 1 - 3
Cariprazine 1 - 3 - 3
Paliperidone 1 3 1 - 3
Quetiapine 1 2 1 1 1
Risperidone 1 1 1 1 1
Valproate 1 1 1 1 2
Carbamazepine 2 2 2 - 3
Haloperidol 2 2 2 1 1
Lithium 2 2 1 1 3
Olanzapine 2 2 1 1 1
ECT 3 4 2 - 3
Oxcarbazepine 3 4 3 - -
Chlorpromazine 4 3 3 - 3
Pimozide 4 3 - - 3
Tamoxifen 4 3 3 - -
Ziprasidone 4 1 1 - 3
Eslicarbazepine NR - - - -
Gabapentin NR NR NR NR -
Lamotrigine NR NR NR NR -
Licarbazepine NR - - - -
rTMS NR - - - -
Topiramate NR NR NR NR -
Verapamil NR - - - -
Phenytoin - 3 - - -
Clozapine - 4 3 - 3
Amisulpride - 4 - - 3
Clonazepam - 4 - - -
Leviracetam - 4 - - -
Lorazepam - 4 - - -
Abbreviations: ECT, electroconvulsive treatment NR, not recommended; rTMS, repetitive Transcranial Magnetic Stimulation.
The grading is not uniform; instead it reflects the grading utilized by individual guidelines and the table aims only to give an image of how different guidelines 
prioritize treatment options).
a NICE and BAP ordering is on the basis of line of treatment.
b Step 2 in the WFSBP guideline would be a combination of two grade “1”.
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rights, and citizen empowerment issues, but usually it also 
improves adherence and collaboration with the therapist, thus 
leading to a better outcome. During the maintenance phase it is 
important to have in mind that at least one-third of BD patients 
frequently fail to take their medication (Scott and Pope, 2002) 
as prescribed, and that nonadherence leads to more frequent 
recurrences, hospitalizations, and sometimes to death by sui-
cide (Muller-Oerlinghausen et al., 1992; Adams and Scott, 2000; 
Colom et al., 2000).
To enhance treatment adherence it is important to recog-
nize the contributing factors (Sajatovic et al., 2004) and involve 
both the patient and his/her family in the decision making 
with psychoeducational support (van Gent and Zwart, 1991; 
Sajatovic et al., 2004). In this context, the collaboration between 
the patient and his/her family with the therapist concerning 
the monitoring of symptoms can lead to the identification of 
periods with a high risk of relapse, and if necessary to adjust-
ments in treatment or to early targeted interventions to reduce 
the intensity and duration of an emerging acute episode.
The successful treatment of the acute episode should be 
perpetuated during the phase that is called continuation and 
may differ from the maintenance phase, although the terms are 
often interchangeably used. Maintenance treatment should be 
kept indefinitely (lifelong) after the diagnosis of BD has been 
confirmed. Exceptions may be patients after a first and single 
manic or mixed episode, and those with a history of a very infre-
quent relapses where physical health risks of medication may 
outweigh benefits. This should be a special issue to deal with 
during psychoeducational interventions.
A difficult question is whether it is wise to continue the 
index medication used for the acute episode. This is an option 
adopted by many guidelines. The position of the CINP guidelines 
Table 4. Level of Recommendation Concerning Monotherapy and Combination Treatment in Acute Bipolar Depression and also for Comorbid 
Anxiety
Monotherapy Combination
Agent/modality Overall BD-I BD-II
Comorbid 
anxiety MS Cbz Lam Li Val
Recommended  
Dosage (mg/d)
Quetiapine 1 3 3 3 - - - - - 300–600
OFC 2 3 - - 2 - - - - 6 + 25; 6 + 50; 12 + 50
Lurasidone 2 - - 3 2 - - - - 20–120
Escitalopram 2 - 3 - - - - - - 10
Fluoxetine 2 - 3 - - - - 4 - 20–80
Valproate 3 3 5 3 - - - - - 500–2500 (50–100 mcg/mL)
Aripiprazole 3 3 - - - - - 5 - 5–30
Imipramine 3 - - - - - - 5 - 75–300
Phenelzine 3 - - - - - - - - 15–90
Olanzapine 4 4 - - - - - - - 5–20
Lamotrigine 4 4 4 - - - - 4 - 50–200
Tranylcypromine 4 4 4 - - - - - - 20–30
Venlafaxine 4 4 4 - - - - - - 75–225
Carbamazepine 4 - - - - - - - - 300–800
Lithium 5 - 4 5 - - 2 - - 600–1800
Paroxetine 5 5 5 3 5 5 - 5 5 20
Gabapentin 5 - - - - - - - -
rTMS 5 - 4 5 - - - - -
Ziprasidone 5 5 - 5 5 - 5 5 5
FEWP - - - - - 1 - - - 36 g/d
Levothyroxine (L-T4) - - - - 2 - - - - 300 mcg/d
Modafinil - - - - 2 - - - - 100–200
Pioglitazone - - - - - - - 2 - 30
Pramipexole - - - - 2 - - - - 1–3
Armodafinil - - - - 4 - - - - 150
Ketamine - - - - 4 - - - - 0.5 mg/kg i.v. (single 
dosage)
L-sulpiride - - - 5 - - - 3 - 50–75
Oxcarbazepine - - - 3 - - - 2 - 600–1200
Agomelatine - - - - 5 - - 5 5
Imipramine - - - - - - - 5 -
Memantine - - - - - - 5 - -
Levetiracetam - - - - 5 - - - -
Bupropion - - - - 5 - - - -
Celecoxib - - - - 5 - - - -
Risperidone - - - 5 5 - - - -
Abbreviations: -, no data; Cbz, carbamazepine; FEWP, Free and Easy Wanderer Plus; Lam, lamotrigine; MS, mood stabilizer; NR, not recommended; OFC, olanzapine-
fluoxetine combination; rTMS, repetitive Transcranial Magnetic Stimulation; Val, valproate.
Recommended dosages for medication options are also shown.
The grading method including the levels of recommendation are described in detail in the 1st and 2nd papers on CINP treatment guidelines, which are included in 
the current supplement.
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is that the acute-phase treatment should be continued for a 
minimum of 2 months after the achievement of full resolution 
of symptoms (and thus the patient has entered remission), and 
after this period treatment should gradually be changed into the 
recommended maintenance treatment.
Of utmost importance is the identification of subsyndromal 
or subthreshold symptoms that are more often of depressive 
polarity. In case of the presence of these clinical features, the 
therapist might consider to add on a treatment that is effica-
cious in acute mania or depression depending on the polarity of 
Table 6. Comparison of the CINP Clinical Guidelines with Other Previously Developed Guidelines for Acute Bipolar Depression
CINP 2017 WFSBP 2013a CANMAT and ISBD 2013 NICE 2014b BAP 2016b
Lurasidone 1 - 2 - 1
OFC 1 3 1 1 1
Quetiapine 1 1 1 1 1
Valproate 2 3 2 1 -
Lithium 2 5 1 1 3
Escitalopram 2 - 3
Fluoxetine 2 3 - - 3
Aripiprazole 3 - NR - -
Imipramine 3 - 4
Phenelzine 3 - -
Carbamazepine 4 5 3 - -
Lamotrigine 4 3 1 1 2
Olanzapine 4 3 3 1 1
Tranylcypromine 4 - - - 4
ECT 5 4 3 - 5
Gabapentin NR - NR - -
Leviracetam - - NR - -
L-thyroxine - 4 - - -
Paroxetine NR - - - 3
Risperidone - - NR - -
rTMS NR - - - -
Ziprasidone NR - NR - -
Abbreviations: ECT, electroconvulsive therapy; NR, not recommended; OFC, olanzapine-fluoxetine combination; rTMS, repetitive Transcranial Magnetic Stimulation.
The grading is not uniform; instead it reflects the grading utilized by individual guidelines and the table aims only to give an image of how different guidelines 
prioritize treatment options.
a WFSBP: Recommendation reflects only monotherapy not considering evidence derived from combination treatment (except OFC).
b NICE and BAP ordering is on the basis of line of treatment.
Table 5. Clinical Guideline to Treat Acute Bipolar Depressive Episodes
1st step • Start with quetiapine, lurasidone, or OFC
• Consider add-on CBT. Never consider CBT as monotherapy
2nd step • Monotherapy with valproate or lithium
• Combination of a mood stabilizer with lurasidone, modafinil, or pramipexole
• Lithium plus pioglitazone
• Carbamazepine plus FEWP
• Add escitalopram or fluoxetine on ongoing therapy
• For the treatment of comorbid anxiety add paroxetine, quetiapine, valproate, or lurasidone, and consider 
mindfulness-based interventions as add-on ongoing therapy
3rd step • Aripiprazole, imipramine, or phenelzine monotherapy
• Lithium plus oxcarbazepine or L-sulpiride
4th step • Olanzapine, lamotrigine, tranylcypromine, or carbamazepine monotherapy
• Venlafaxine preferably in combination with an antimanic agent
• Armodafinil or ketamine on a mood stabilizer
• Lithium plus fluoxetine or lamotrigine
5th step • ECT
• Various combinations of medication according to anecdotal knowledge or the personal experience of the 
therapist
Not recommended Monotherapy with donepezil, paroxetine (except for comorbid anxiety), ziprasidone, gabapentin, lithium 
and rTMS, combination of any mood stabilizer with agomelatine, paroxetine, ziprasidone, bupropion, 
celecoxib, levetiracetam, lisdexamfetamine or risperidone, Memantine plus lamotrigine and lithium plus 
aripiprazole, donepezil or imipramine. Not recommended also risperidone or ziprasidone for the treatment 
of concomitant anxiety
Abbreviations: CBT, cognitive behavioral treatment; Cbz, carbamazepine; ECT, electroconvulsive therapy; FEWP, Free and Easy Wanderer Plus; IPSRT, interpersonal 
and social rhythms therapy; Lam, lamotrigine; MS, mood stabilizer; OFC, olanzapine fluoxetine combination; rTMS, repetitive Transcranial Magnetic Stimulation; Val, 
valproate.
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these subthreshold or subsyndromal symptoms. However, it is 
obvious that this might lead to polypharmacy with little scien-
tific support. As discussed in detail in the accompanying papers, 
BD is associated with frequent comorbidity that includes alco-
hol and substance abuse, anxiety disorders, personality dis-
orders, and higher rates of general medical conditions. The 
management of these comorbid conditions and especially of 
those medical conditions that are associated with reduced life 
expectancy should be considered high priority.
Essentially BD is a chronic disease displaying a complex 
clinical picture with high psychiatric and medical comorbid-
ity, which demands high-quality intensive and expensive care. 
A  multidisciplinary team approach following an organized 
step-by-step manner with interventions and activities that also 
extend in the community is often mandatory (Wagner, 1998).
A number of specific clinical variables with research data sup-
porting their usefulness in the decision-making process should 
be assessed. These include the predominant polarity, and the 
presence of psychotic features, mixed episodes, and rapid cycling. 
Other clinical features might be important (e.g., suicidality); how-
ever, there are no hard data to dictate their targeted treatment.
More specifically, first consider whether a predominant polarity 
is present when starting maintenance treatment (Carvalho et al., 
2015). Then consider the possibility to stage the disorder, having in 
mind that probably the predominant polarity changes into depres-
sive with the progression of the disease. Consider the presence of 
psychotic symptoms in the course of the disorder. Search for the 
recurrent emergence of mixed episodes in the past and decide 
whether the patient should be classified as rapid cycling.
If the treatment during the most recent episode needs to be 
completely different from the options that are suggested for 
the maintenance phase in the specific patient, keep it for the 
continuation phase and gradually taper it against one of the 
recommended treatments for the maintenance phase. An over-
view of the data the clinical guideline is based on is shown in 
Table 7.
First step:
• Take predominant polarity (if evident) into consideration
• Start with lithium, aripiprazole, olanzapine, paliperidone, 
quetiapine, or risperidone, including Risperidone Long Act-
ing Injectable (RLAI) monotherapy depending on predomi-
nant polarity
• Consider CBT or psychoeducation as add-on to medica-
tion on the basis of clinical judgement of the therapist and 
according to the patient preference and to availability. Never 
consider CBT or psychoeducation as monotherapy
Second step:
• Add fluoxetine, lamotrigine, or lithium on the first-step 
option (depending on predominant polarity)
• Lithium plus carbamazepine
• Quetiapine plus lithium or valproate
• Olanzapine or aripiprazole plus a mood stabilizer
Third step:
Add RLAI, valproate, carbamazepine, or N-acetylcysteine on sec-
ond step treatment if not previously used
Fourth step:
• Take into consideration the predominant polarity and add an 
agent with proven efficacy against the acute phase no matter 
whether it has proven maintenance efficacy
• Lithium plus lamotrigine
• Consider adding venlafaxine or haloperidol
Table 7. Level of Recommendation during the Maintenance Phase and the Efficacy in the Prevention of Manic, Mixed, or Depressive Episodes 
as Well as Recommended Dosages
Agent/modality
Monotherapy Combination
Recommended dosageManic depressive Mixed MS Cbz Lam Li Val
Quetiapine 2 2 - 1 - - - - 300–800 mg/d
Olanzapine 2 2 2 4 - - - - 5–20 mg/d
Lithium 2 3 - - - - - - 0.6–1.2 mEq/L
Lamotrigine 4 4 - - - - - - 50–400 mg/d
Psychoeducation - - -- 3 - - - -
Aripiprazole 1 5 - 2 - 5 - 5 10–30 mg/d
RLAI 1 5 - 2 - - - - 25–50 mg/biweekly
Paliperidone 2 5 - - - - - - 3–12 mg/d
Valproate 4 3 - - - - - - 45–100 mg/L
Carbamazepine 4 4 - - - - - - 4–12 mg/L
Ziprasidone - - - 4 - - - - 80–160 mg/d
Fluoxetine - 2 - - - - - - 10–40 mg/d
CBT - - - 2 - - - -
Phenytoin - - - 2 - - - - Mean studied 380 mg/d (blood 
levels 10 microgram/mL)
Paroxetine - - - 3 - - - - 20 mg/d
N-acetyl cysteine - - - 4 - - - - 2 g/d
Imipramine 5 5 - - - - 5 -
Memantine - - - 5 - - - -
Oxcarbazepine - - - - - - 5 -
Perphenazine - - - 5 - - - -
Abbreviations: CBT, cognitive behavioral therapy; Cbz, carbamazepine; Lam, lamotrigine; MS, mood stabilizer; RLAI, risperidone long acting injection; Val, valproate.
The grading method including the levels of recommendation are described in detail in the 1st and 2nd papers on CINP treatment guidelines, which are included in 
the current supplement.
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Fifth step:
• Consider any combinations from steps 1 to 4 that have not 
been tried
• Consider maintenance ECT
• Various combinations of medication according to anecdotal 
knowledge or the personal experience of the therapist
• Consider Interpersonal and Social Rhythms Therapy (IPSRT) 
as add-on to medication on the basis of clinical judgement 
of the therapist and according to the patient preference and 
to availability. Never consider IPSRT or psychoeducation as 
monotherapy
Not recommended:
• Adding memantine or perphenazine on a mood stabilizer
• Aripiprazole plus lamotrigine or valproate
• Lamotrigine plus valproate
• Lithium plus imipramine or oxcarbazepine.
The chart of the guideline for the maintenance phase is shown 
in Table 8. The comparison of the CINP guidelines to other previ-
ously developed guidelines for the maintenance phase is shown 
in Table 9. It should be noted that there are no adequately con-
trolled trials supporting the efficacy of oxcarbazepine.
Duration of Maintenance Treatment
There are no data concerning the duration of maintenance 
treatment. As mentioned in the first CINP guidelines paper, in 
70% of cases the course resembles that of a recurrent episodic 
illness, while in 25% of cases there is a chronic course without 
clear remissions between episodes. In only 5% there is a single 
episode of mania, and this probably depends on the duration of 
the follow-up. BD is almost by definition a lifelong disorder, and 
thus it requires lifelong maintenance treatment or at least close 
observation and timely interval treatment initiation in selected, 
reliable patients knowing their early warning signs.
The only medical reasons for stopping maintenance treat-
ment are poor tolerability, safety reasons, and continuous non-
adherence. Also in some patients in whom medication does 
little or no difference, especially during the advanced stages of 
the disorder, a more palliative type rather than an aggressive 
maintenance treatment might be preferable. This is a very sensi-
tive issue and it is open to debate.
Many patients will refuse long-term pharmacotherapy, or 
manifest poor adherence. Psychoeducational interventions have 
been proven to be efficacious during the earlier stages of the dis-
order. Since there is lack of knowledge concerning the efficacy of 
other psychotherapeutic interventions, psychoeducation alone 
or together with cognitive remediation could be applied to those 
patients with severe disability and residual symptoms, and to 
those with poor insight and adherence.
Special Cases and Populations
Agitation
Agitation is most often present during periods of acute manic or 
mixed episodes, but it is not unusual during periods of depres-
sion, especially with mixed depressive states. The presence of 
agitation acts as a barrier to therapy, prevents the establishment 
of a therapeutic alliance, and poses a risk to the health and life 
of the patient and others (Garriga et al., 2016).
It is important to provide a calming environment with 
reduced stimuli and to make any effort to establish rapport with 
the patient. In case this fails, then involuntary treatment might 
be necessary according to local legislation. The evidence-based 
pharmaceutical interventions recommended are (Chouinard 
et al., 1993; McElroy et al., 1996; Hirschfeld et al., 1999; Meehan 
et al., 2001; Citrome, 2012; Kwentus et al., 2012):
• Intramuscular haloperidol (5–10 mg) at 0, 30, and 60 minutes
• Intramuscular olanzapine (10  mg, first 2 injections; 5  mg, 
third injection)
• Inhaled loxapine 5 mg or 10 mg single dose in 24 hours
Combination of an antipsychotic with
• Clonazepam injections (1–2 mg) at 0, 30, and 60 minutes
• Lorazepam injections (2  mg, first 2 injections; 1  mg, third 
injection). In case the patient accepts oral therapy and the 
therapist wishes to avoid injectables, an antipsychotic in 
monotherapy or in combination with a benzodiazepine 
could be the choice. Valproate oral loading of 20 to 30 mg/
kg/d is also an option
Table 8. Clinical Guideline to Treatment during the Maintenance Phase for Bipolar Disorder
1st step • Start with lithium, aripiprazole, olanzapine, paliperidone, quetiapine, or risperidone (including RLAI) 
monotherapy
• Consider CBT or psychoeducation as add-on to medication. Never consider CBT or psychoeducation as 
monotherapy
• Take predominant polarity (if present) into consideration
2nd step • Add fluoxetine or lithium on the first-step option
• Lithium plus carbamazepine
• Quetiapine plus lithium or valproate
• Olanzapine or aripiprazole plus a mood stabilizer
3rd step Add RLAI, valproate, carbamazepine, lamotrigine, or N-acetylcysteine on second-step treatment
4th step Take into consideration the predominant polarity and add an agent with proven efficacy against the acute 
phase no matter whether it has proven maintenance efficacy.
Consider adding venlafaxine or haloperidol
5th step Consider any combinations from steps 1–4 that have not been tried
Consider maintenance ECT
Various combinations of medication according to anecdotal knowledge or the personal experience of the 
therapist
Not recommended Adding memantine or perphenazine on a mood stabilizer, aripiprazole plus lamotrigine or valproate, 
lamotrigine plus valproate, lithium plus lamotrigine, imipramine, or oxcarbazepine.
Abbreviations: ECT, electroconvulsive therapy; RLAI, risperidone long acting injectable.
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Combinations of injectables with oral medication could also 
be an option depending on availability. In principle benzodiaz-
epines should not be used as monotherapy beyond the acute 
emergency room setting in BD patients.
Pregnancy, Breast-Feeding, and the Use of Oral Contraceptives
Since around one-half of pregnancies are unplanned (Bergman 
et al., 1992), the psychoeducation of bipolar females concerning 
the course of the disorder and issues pertaining to contracep-
tives, pregnancy, postpartum, and breast-feeding and the effect 
medication have on the fetus is essential.
Risks (teratogenic effects) and benefits (prevention of recur-
rence) of medication treatment need to be discussed with the 
patient and her spouse at the earliest. In principle, maintenance 
treatment should be paused during pregnancy and especially 
during the first trimester if possible. This might not always be 
an option, especially in women with a high risk of recurrence. 
There are no controlled data on which treatment option is most 
efficacious and safest, especially in early pregnancy; therefore 
the general guidelines are in place. If possible pharmacotherapy 
should be avoided at least during the first trimester, and ECT 
might be an alternative option in severely ill patients.
If a decision in favor of medication treatment has been 
made, at least some patients might require higher doses of 
medication because of physiological changes related to preg-
nancy. Decrease in dosage might be advisable during the last 
few weeks before delivery (Altshuler and Hendrick, 1996). The 
agents with a known teratogenic effect are lithium, valproate, 
carbamazepine, and lamotrigine in doses >200 mg/d. Valproate 
and carbamazepine should be avoided in any case; continua-
tion of lithium treatment might be justified in selected patients 
with their informed consent as the risk of heart malformations 
has been overestimated in the past (Burt and Rasgon, 2004; 
Yacobi and Ornoy, 2008). Atypical antipsychotics and lamotrig-
ine monotherapy in doses <200 mg/d are reasonable choices, 
although the data on their safety during pregnancy are still 
limited. ECT is always an option; it is relatively safe with no 
data suggesting any teratogenic effect (Miller, 1994; Walker and 
Swartz, 1994; Echevarria Moreno et al., 1998; Bhatia et al., 1999; 
Kasar et al., 2007; Richards, 2007; Bulut et al., 2013; Gahr et al., 
2013; Spodniakova et al., 2014; Leiknes et al., 2015). After deliv-
ery the most reasonable decision would be to start immediately 
with maintenance treatment, since the risk for a postpartum 
recurrence is high and avoid breast-feeding because most phar-
macotherapeutic agents are excreted in the milk. Some patients 
might choose to breastfeed, but this should only be done after 
a detailed discussion of the risks and benefits, and the infant 
should be closely and carefully monitored. In this case, it might 
be better to use medication with short half-lives and to take 
them after breastfeeding to minimize the exposure of the infant. 
Unfortunately, the literature on treatment during the postpar-
tum period is limited; therefore, the general guideline should be 
followed. Divalproex and carbamazepine are considered more 
compatible with breastfeeding compared with lithium (Austin 
and Mitchell, 1998; American Academy of Pediatrics Committee 
on Drugs, 2001; Burt et al., 2001; Ernst and Goldberg, 2002; Burt 
and Rasgon, 2004; Yonkers et al., 2004; Nice and Luo, 2012).
Management of Somatic Problems in BD Patients
Bipolar patients might present with a variety of somatic prob-
lems. The cause of them is variable and difficult to identify, but 
it includes a general higher risk observed in BD patients, and the 
sedentary lifestyle as well as the direct effect of medication as 
additional risk factors.
Increase in appetite, weight gain, and obesity are com-
mon problems in BD patients and are associated both with the 
Table 9. Comparison of the CINP Guidelines to Other Previously Developed Guidelines for Maintenance Phase
CINP 2017 WFSBP 2013a CANMAT and ISBD 2013 NICE 2014b BAP 2016b
Aripiprazole 1 1 1 - 3
Lithium 1 1 1 1 1
Olanzapine 1 2 1 1 2
Paliperidone 1 3 2 - 3
Quetiapine 1 1 1 1 2
Risperidone 1 2 - - 3
RLAI 1 - 1 - 2
OFC 2 - 2 - -
Carbamazepine 2 4 2 - 2
Valproate 2 3 1 1 2
Lamotrigine 3 1 1 - 2
Haloperidol 4 - - - 3
Venlafaxine 4 - - - -
ECT 5 4 3 - -
Ziprasidone 5 3 - - 3
Continue most recent 
episode treatment
NR - - 1 -
Antidepressants - 3 NR - 4
Asenapine - 4 3 - 3
Gabapentin - 4 NR NR -
Topiramate - 4 NR - -
Abbreviations: ECT, electroconvulsive therapy; NR, not recommended; OFC, olanzapine-fluoxetine combination; RLAI, risperidone long-acting injectable.
The grading is not uniform; instead it reflects the grading utilized by individual guidelines and the table aims only to give an image of how different guidelines 
prioritize treatment options.
a WFSBP: Recommendation grades and subsequent positioning could be either based on efficacy in the prevention of mania, depression or any episode. Thus,  
numbers do not reflect the sequence of treatment in an individual patient.
b NICE and BAP ordering is on the basis of line of treatment.
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disease and its treatment. Weight gain is perceived by patients 
and especially by young females to be a distressing side effect, 
and it frequently leads to poor adherence with treatment. 
Diabetes mellitus could develop as a consequence of weight 
gain, but is has been also reported in patients as a direct adverse 
effect of medication without the mediating effect of weight 
gain. Those patients with risk factors for diabetes (e.g., obe-
sity, family history of diabetes) should undergo a full medical 
investigation of their individual risk to diabetes, hypertension, 
and dyslipidaemia before the initiation of treatment and peri-
odically thereafter. During the maintenance phase, all patients 
should be monitored for symptoms and signs, including poly-
dipsia, polyuria, and polyphagia, and if appropriate a laboratory 
investigation should be carried out. If necessary, treatment of 
diabetes and dyslipidaemia should be initiated and medication 
changes strongly considered.
Severe adverse effects specific to lithium are kidney and 
thyroid toxicity. Therefore, lithium should be gradually titrated 
and taken with food to reduce nausea, and plasma creatinine 
concentrations, Glomerular filtration rate, and thyroid function 
should be investigated at least once a year.
Discussion
The first operational treatment guidelines for BD were those of 
the American Psychiatric Association in 1994 (APA, 1994, 1995). 
Since then, a significant number of guidelines have been devel-
oped and some of them are regularly updated (APA, 1994, 1995, 
2002; Suppes et al., 1995, 2001, 2002, 2003; Frances et al., 1996; 
1997; AACAP, 1997; Goodwin et al., 1997, 2003, 2009, 2016; Jobson, 
1997; Kusumakar et al., 1997; McClellan and Werry, 1997; Gilbert 
et al., 1998; Barreira et al., 1999; Bauer et al., 1999; Rush et al., 
1999; Dennehy, 2000; Goldberg, 2000; Sachs et  al., 2000; Allen 
et al., 2001; Montgomery, 2001; Grunze et al., 2002, 2003, 2004, 
2009, 2010, 2013; Licht et al., 2003; Rush et al., 2003; Hirschfeld, 
2005; Yatham et al., 2005, 2006, 2008, 2009, 2013a, 2013b; National 
Collaborating Centre for Mental Health, 2006; O’Dowd, 2006; 
Nolen et  al., 2008; Jon et  al., 2009; Ng et  al., 2009; Frye et  al., 
2011; Beaulieu et al., 2012; Bond et al., 2012; McIntyre et al., 2012; 
Rosenbluth et  al., 2012; Schaffer et  al., 2012; Mohammad and 
Osser, 2014; NICE, 2014; Malhi et al., 2015; Ostacher et al., 2015; 
Woo et al., 2015).
It is not surprising that guidelines place emphasis on differ-
ent kinds of treatments and utilize a different concept of the 
disorder, since the data are incomplete and subject to varying 
interpretation. In general, as an approach, treatment guidelines 
constitute one of the important developments in the field of psy-
chiatry, following the introduction of operationalized diagnostic 
criteria in the frame of modern classification systems and the 
promotion of evidence-based medicine (EBM) also in psychiatry. 
They emerged as an important tool to summarize and appraise 
the research data and, to the extent this is possible, to standard-
ize treatment on the basis of evidence. They also emerged as 
a response to the need of many clinicians for algorithms that 
translate research findings into the everyday clinical practice 
by organizing information from diverse sources into an easily 
accessible and reliable format.
Although it is expected that, in principle, the development 
of algorithms obeys the rules of EBM and is based primarily on 
research data from studies conducted in a rigorous way, often 
expert opinion or clinical consensus supersede the evidence. In 
the last few years, the consumer opinion as well as economic 
issues have had increasing strength and importance and may 
play a significant role in the shaping of steps. The standard 
approach in the development of algorithms as this has been 
shaped in the last 20 years is to utilize EBM standards for the 
earlier steps; however, as algorithms move from earlier to later 
steps, the evidence becomes more and more insufficient, and in 
most cases expert opinion or clinical consensus gradually take 
over. Socioeconomic forces from patient advocates, the industry, 
and the economic interests of the government and insurance 
companies exert pressure already from the first step and up to 
the end of the procedure or interventions.
Eventually, the use of algorithms and guidelines is supposed 
to bring benefits for the patients in terms of a more favorable 
overall outcome as it combines efficacy and safety/tolerabil-
ity. It is also supposed to bring benefits for the health system 
in general, since the use of algorithms and guidelines facili-
tates clinical decision making, reduces clinically inappropriate 
or cost-inefficient clinical practice decisions, provides similar 
treatment across different settings, and provides a metric to 
assess patient response and a framework to estimate the cost of 
treatment (Fountoulakis et al., 2005).
However, there are several potential risks associated with 
the use of algorithms and guidelines (Rush et al., 1999). The big-
gest problem is that often the evidence might be insufficient to 
lead to the development of a reliable algorithm, and the con-
sensus panels whose decisions will cover the gap often express 
biased opinions. The use of algorithms may increase the costs 
disproportionally in comparison with benefits, and this poses 
important ethical dilemmas, especially when efficacy collides 
with safety and cost. Justified deviations from algorithms may 
constitute a case for legal action by malpractice lawyers.
The various treatment guidelines generally seem to have a 
common starting point, best described by the 1994 APA guide-
lines (APA, 1994), which interestingly seem to reflect the opinion 
of many clinicians still today. Overall it seems that disagree-
ments are more than agreements even though all treatment 
guidelines claim to be evidence based. Probably this is because 
of the different way to approach and utilize the data. The com-
parison of the current CINP clinical guideline with 3 other guide-
lines (NICE, CANMAT/ISBD, WFSBP and BAP) is shown in Tables 3, 
6, and 9. The current CINP guidelines are the most recent fully 
updated and fully evidence-based guidelines on the treatment 
of BD. They also include recommendations concerning the use 
of psychotherapeutic interventions again on the basis of avail-
able evidence. It is of note that the adherence of the workgroup 
to the evidence in a strict way produced guidelines that some-
how differ radically from other previously developed guidelines. 
These differences include the role of specific antidepressants 
and the priority in the use of traditional agents like lithium, val-
proate, or carbamazepine. The focus on specific clinical charac-
teristics, including predominant polarity, mixed features, rapid 
cycling is also a novel approach, and it has been utilized in the 
development of the specific algorithm and to a lesser extent 
in the development of the clinical guidelines. In the past, only 
predominant polarity had been utilized by the BAP guidelines 
(Goodwin, 2009).
It is evident that there are many issues that need further 
study, data are sparse and insufficient, and many questions 
remain unanswered. The most important and still unmet need 
is to be able to merge all the guidelines that concern different 
phases of the illness into a single one and in this way consider 
BD as a single unified disorder, which is the real world fact. 
However, to date the research data do not permit such a unified 
approach. It is also important to note that in spite of the publi-
cation of various treatment guidelines, clinicians do not seem 
to widely adopt any of them. Their impact on clinical practice 
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is quite limited even in the US. After the publication of the first 
APA 1994 guidelines, only about 16% of manic patients without 
psychotic features, 38% with mania with psychotic features, 
31% of bipolar depressed with psychotic features, and 17% of 
bipolar depressed without psychotic features were reported to 
be treated according to treatment guidelines (Lim et al., 2001).
The pressure to develop guidelines for the treatment of 
severe and disabling mental disorders becomes stronger and 
stronger because of the need to provide a standardized, better, 
and more cost-effective treatment; however, empirical data are 
not always sufficient and the evaluation of guidelines in the 
real-world environment does not always support their use, as 
many times they lead to an increased cost without an impres-
sive improvement in the treatment outcome. But the least these 
algorithms may achieve is to ensure a minimum quality of treat-
ment and care and the minimum necessary discipline from the 
side of the therapist. Although the wider utilization of treatment 
guidelines is a universal need, at the same time the psychiat-
ric community should guard the right of the therapist to make 
independent decisions concerning treatment on the basis of the 
individual patient and available scientific data; that means algo-
rithms cannot replace education and training and may not be 
considered a golden standard of treatment, the deviation from 
which needs to be justified. Such an extreme position may lead 
to unnecessary legal complications.
One issue that warrants further study and attention is the 
fact that not all agents and therapeutic modalities are avail-
able in every country and not even within the same country, 
since sophisticated psychosocial approaches or ECT are often 
not accessible to the majority of patients. The current guideline 
did not take into consideration this issue but rather stuck to the 
body of hard evidence. This might make problematic specific 
aspects and steps of the guideline in some countries, especially 
when economic criteria are also implemented.
Concerning the current clinical guidelines, it is obvious that 
those who will choose to utilize them in their everyday clini-
cal practice should have in mind that evidence-based guidelines 
like the CINP guidelines are limited by the data that are avail-
able. The workgroup hopes that they will constitute a valuable 
tool to guide the everyday clinical practice for the benefit of the 
patients, their families, and society, but on the other hand clini-
cians must exercise caution and make clinical decisions tailored 
to individual cases on the basis of a specific risk-benefit analysis 
suitable for the particular patient.
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